Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

CD4(+)Foxp3(+) regulatory T cell therapy in transplantation.

Tang Q, Bluestone JA, Kang SM.

J Mol Cell Biol. 2012 Feb;4(1):11-21. doi: 10.1093/jmcb/mjr047. Epub 2011 Dec 14. Review.

2.

Double negative regulatory T cells in transplantation and autoimmunity: recent progress and future directions.

Juvet SC, Zhang L.

J Mol Cell Biol. 2012 Feb;4(1):48-58. doi: 10.1093/jmcb/mjr043. Review.

3.

Induced Foxp3(+) regulatory T cells: a potential new weapon to treat autoimmune and inflammatory diseases?

Lan Q, Fan H, Quesniaux V, Ryffel B, Liu Z, Zheng SG.

J Mol Cell Biol. 2012 Feb;4(1):22-8. doi: 10.1093/jmcb/mjr039. Epub 2011 Nov 22. Review.

4.

Impact of immunosuppressants on the therapeutic efficacy of in vitro-expanded CD4+CD25+Foxp3+ regulatory T cells in allotransplantation.

Lim DG, Koo SK, Park YH, Kim Y, Kim HM, Park CS, Kim SC, Han DJ.

Transplantation. 2010 Apr 27;89(8):928-36. doi: 10.1097/TP.0b013e3181d3c9d4.

PMID:
20305583
5.

CD4+ T-regulatory cells: toward therapy for human diseases.

Allan SE, Broady R, Gregori S, Himmel ME, Locke N, Roncarolo MG, Bacchetta R, Levings MK.

Immunol Rev. 2008 Jun;223:391-421. doi: 10.1111/j.1600-065X.2008.00634.x. Review.

PMID:
18613849
6.
7.

Dendritic cells expand antigen-specific Foxp3+ CD25+ CD4+ regulatory T cells including suppressors of alloreactivity.

Yamazaki S, Inaba K, Tarbell KV, Steinman RM.

Immunol Rev. 2006 Aug;212:314-29. Review.

PMID:
16903923
8.

Efficient and selective prevention of GVHD by antigen-specific induced Tregs via linked-suppression in mice.

Semple K, Yu Y, Wang D, Anasetti C, Yu XZ.

Biol Blood Marrow Transplant. 2011 Mar;17(3):309-18. doi: 10.1016/j.bbmt.2010.12.710. Epub 2011 Jan 9.

9.

FOXP3+ regulatory T cells: from suppression of rejection to induction of renal allograft tolerance.

Dummer CD, Carpio VN, Gonçalves LF, Manfro RC, Veronese FV.

Transpl Immunol. 2012 Jan;26(1):1-10. doi: 10.1016/j.trim.2011.08.009. Epub 2011 Sep 13. Review.

PMID:
21939765
10.

Role of naturally arising regulatory T cells in hematopoietic cell transplantation.

Nguyen VH, Zeiser R, Negrin RS.

Biol Blood Marrow Transplant. 2006 Oct;12(10):995-1009. Review.

11.

Effective expansion of alloantigen-specific Foxp3+ CD25+ CD4+ regulatory T cells by dendritic cells during the mixed leukocyte reaction.

Yamazaki S, Patel M, Harper A, Bonito A, Fukuyama H, Pack M, Tarbell KV, Talmor M, Ravetch JV, Inaba K, Steinman RM.

Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2758-63. Epub 2006 Feb 10.

12.

Comparative analysis of dendritic cells and anti-CD3/CD28 expanded regulatory T cells for application in transplantation.

Zeng M, Guinet E, Nouri-Shirazi M.

Transpl Immunol. 2009 Dec;22(1-2):82-92. doi: 10.1016/j.trim.2009.07.004. Epub 2009 Jul 25.

PMID:
19635560
13.

Autologous stem cell transplantation aids autoimmune patients by functional renewal and TCR diversification of regulatory T cells.

Delemarre EM, van den Broek T, Mijnheer G, Meerding J, Wehrens EJ, Olek S, Boes M, van Herwijnen MJ, Broere F, van Royen A, Wulffraat NM, Prakken BJ, Spierings E, van Wijk F.

Blood. 2016 Jan 7;127(1):91-101. doi: 10.1182/blood-2015-06-649145. Epub 2015 Oct 19.

14.

Therapeutic potential of induced and natural FoxP3(+) regulatory T cells for the treatment of Graft-versus-host disease.

Prinz I, Koenecke C.

Arch Immunol Ther Exp (Warsz). 2012 Jun;60(3):183-90. doi: 10.1007/s00005-012-0172-3. Epub 2012 Apr 5. Review.

PMID:
22476537
15.

Human T regulatory cell therapy: take a billion or so and call me in the morning.

Riley JL, June CH, Blazar BR.

Immunity. 2009 May;30(5):656-65. doi: 10.1016/j.immuni.2009.04.006. Review.

16.

Alloantigen-specific de novo-induced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD.

Koenecke C, Czeloth N, Bubke A, Schmitz S, Kissenpfennig A, Malissen B, Huehn J, Ganser A, Förster R, Prinz I.

Eur J Immunol. 2009 Nov;39(11):3091-6. doi: 10.1002/eji.200939432.

17.

Regulatory T cells in kidney disease and transplantation.

Hu M, Wang YM, Wang Y, Zhang GY, Zheng G, Yi S, O'Connell PJ, Harris DC, Alexander SI.

Kidney Int. 2016 Sep;90(3):502-14. doi: 10.1016/j.kint.2016.03.022. Epub 2016 Jun 3. Review.

PMID:
27263492
18.

In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia.

Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E, Piwnica-Worms DR, DiPersio JF.

Blood. 2010 Jul 8;116(1):129-39. doi: 10.1182/blood-2009-12-257253. Epub 2010 Apr 27.

19.

Foxp3, Regulatory T Cell, and Autoimmune Diseases.

Tao JH, Cheng M, Tang JP, Liu Q, Pan F, Li XP.

Inflammation. 2017 Feb;40(1):328-339. doi: 10.1007/s10753-016-0470-8. Review.

PMID:
27882473
20.

Host Foxp3+CD4+ Regulatory T Cells Act as a Negative Regulator of Dendritic Cells in the Peritransplantation Period.

Inoue T, Ikegame K, Kaida K, Okada M, Yoshihara S, Tamaki H, Fujimori Y, Soma T, Ogawa H.

J Immunol. 2016 Jan 1;196(1):469-83. doi: 10.4049/jimmunol.1402950. Epub 2015 Nov 30.

Supplemental Content

Support Center